Signal #144242 · SEC 8-K

$ACRS SEC Filing Alert & Real-Time AI Stock Impact Analysis

Public T0 SEO entry. Full AI score & bullets unlock after 4 hours (VIP: instant).

FAQ: $ACRS filing catalyst

Why did $ACRS trigger an AI stock catalyst alert?

$ACRS triggered a Stock Catalyst AI alert on 2026-11-05 00:00:00 UTC for a SEC 8-K filing (AI Score: -1.0/10). Headline: Aclaris Therapeutics Reports Q3 Net Loss Widened to $18.5M, Cash at $204.6M. Key points: - Q3 net loss expanded to $18.5M ($0.12/share) vs $14.6M ($0.12/share) in Q3 2025. - Cash, equivalents, and marketable securities reached $204.6M as of September 30, 2026. - Clinical timelines reaffirmed for Bosakitug in AD; Phase 2b Modzatinib trial initiation set for Q4 2026.

How did $ACRS stock react after the SEC filing?

After the SEC 8-K for $ACRS, observed market reaction: T0 price $3.68. Past moves do not guarantee future results.

Where can I get real-time $ACRS SEC filing alerts?

Stock Catalyst AI pushes real-time SEC 8-K alerts for $ACRS via Telegram and the VIP Web Terminal from €10/month.

$ACRS

$ACRS – Aclaris Therapeutics Reports Q3 Net Loss Widened to $18.5M, Cash at $204.6M

Aclaris Therapeutics, Inc.

2026-11-05 00:00:00 UTC · SEC 8-K · All $ACRS

Unlocked archive · Analyzed in <2s at T0

Neutral AI Sentiment (-1.0 / 10)

Q3 net loss expanded to $18.5M ($0.12/share) vs $14.6M ($0.12/share) in Q3 2025.
Cash, equivalents, and marketable securities reached $204.6M as of September 30, 2026.
Clinical timelines reaffirmed for Bosakitug in AD; Phase 2b Modzatinib trial initiation set for Q4 2026.

Unlock Live VIP Terminal & Telegram – €10/mo Original filing →